SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kelderman Kim
(Last) (First) (Middle)
614 MCKINLEY PLACE NE
(Street)
MINNEAPOLIS MN 55413
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Pres. Diagnostics & Genom
3. Date of Earliest Transaction (Month/Day/Year)
08/05/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/05/2023 M 8,060 A $0 23,264 D
Common Stock 08/05/2023 F 4,139 D $82.17 19,125 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $37.7 (1) 05/01/2025 Common Stock 27,392 27,392 D
Stock Option (Right to Buy) $44.33 (1) 08/08/2025 Common Stock 48,176 48,176 D
Stock Option (Right to Buy) $44.33 (1) 08/08/2025 Common Stock 36,132 36,132 D
Stock Option (Right to Buy) $47.6 (1) 08/07/2026 Common Stock 47,844 47,844 D
Stock Option (Right to Buy) $47.6 (1) 08/07/2026 Common Stock 63,792 63,792 D
Stock Option (Right to Buy) $66.97 (1) 08/05/2027 Common Stock 35,964 35,964 D
Stock Option (Right to Buy) $66.97 (1) 08/05/2027 Common Stock 33,300 33,300 D
Restricted Stock Units (2) 08/05/2023 M 8,060 (3) (3) Common Stock 8,060 $0 0 D
Stock Option (Right to Buy) $66.97 (4) 08/05/2027 Common Stock 47,952 47,952 D
Restricted Stock Units (2) (5) (5) Common Stock 4,980 4,980 D
Stock Option (Right to Buy) $120.46 (5) 08/06/2028 Common Stock 19,456 19,456 D
Stock Option (Right to Buy) $120.46 (6) 08/06/2028 Common stock 25,944 25,944 D
Restricted Stock Units (2) (7) (7) Common Stock 6,984 6,984 D
Stock Options (Right to Buy) $94.52 (7) 08/15/2029 Common Stock 21,704 21,704 D
Stock Options (Right to Buy) $94.52 (8) 08/15/2029 Common Stock 28,940 28,940 D
Explanation of Responses:
1. Fully exercisable.
2. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
3. On 8/5/2023, the Board of Directors certified vesting of 8,060 performance RSUs.
4. Options to purchase 11,988 shares vest on each of 8/5/2021, 8/5/2022, 8/5/2023 and 8/5/2024.
5. Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
6. Options to purchase 12,972 shares are vested. Options to purchase 6,488 shares vest on 8/6/2024 and options to purchase 6,484 shares vest on 8/6/2025.
7. Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
8. Options to purchase 7,236 shares vest on each of 8/15/2023, 8/15/2024 and 8/15/2026 and options to purchase 7,232 shares vest on 8/15/2025.
Remarks:
On November 28, 2022, the Company completed a four-for-one stock split. All common stock amounts and exercise prices in the filing relating to securities acquired prior to November 28, 2022 have been adjusted to reflect the four-for-one stock split.
/s/ Andrew Nick, Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed. 08/08/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.